In 2023, Merck, Sanofi, and Fujifilm Cellular Dynamics collaborated as part of the IMI2 NeuroDerisk initiative to perform a comparative assessment of 2D and 3D hiPSC-derived neuronal platforms and their ability to predict clinical seizure liability. AxoSim’s microBrain™ platform was successfully utilized across multiple laboratory sites and showed high concordance with preclinical mouse brain slice models, supporting further investigation of the platform in neuropharmacological safety screening.
